24 July 2024 - Kye Pharmaceuticals today announced that it has entered into a license, supply and commercialisation agreement with Catalyst Pharmaceuticals, securing exclusive Canadian commercial rights to Agamree (vamorolone), an novel corticosteroid for the treatment of Duchenne muscular dystrophy. 

Under the terms of the agreement, Catalyst will supply the product to Kye, who will assume full responsibility for obtaining regulatory approval for Agamree for the treatment of Duchenne muscular dystrophy from Health Canada and all future aspects of commercialisation of the product within Canada.

Read Kye Pharmaceuticals press release